Imeta Nasal Spray (Mometasone Furoate)

Adult dosage

Allergic rhinitis: Spray twice for each nostril once daily (total daily dose 0.2 mg). If symptoms improve, the frequency can be reduced to once for each nostril (total daily dose 0.1 mg). If symptoms do not improve, the dose can be increased to a maximum of 4 sprays (total daily dose 0.4 mg) for each nostril once daily. Nasal polyps: Spray twice for each nostril once daily (total daily dose 0.2 mg).

Children's dosage

Allergic rhinitis: Spray once for each nostril once daily (total daily dose 0.1 mg).

This medication should not be used in patients with hypersensitivity to this medication or its components, or in those with untreated local infections. Patients who have recently undergone nasal surgery or have nasal diseases, septal ulcers, or nasal trauma should refrain from using it until wound healing is complete. It should not be administered to infants under 2 years of age. Patients with active or latent tuberculosis, systemic infections, or herpes simplex in the eyes should use it cautiously, and those with recurrent nosebleeds should be aware of the potential for worsening bleeding. Patients at risk for chickenpox or measles should also exercise caution, and the efficacy of this medication has not been sufficiently studied in patients with unilateral nasal polyps or cystic fibrosis-related nasal polyps. Women who are pregnant or may become pregnant, as well as nursing mothers, should use it cautiously after consulting with a physician. This medication can cause side effects such as headache, nosebleeds, cough, upper respiratory infections, and rarely severe allergic reactions like anaphylaxis; if any unusual symptoms occur, discontinue use immediately and seek medical attention. Prolonged high-dose use may lead to systemic side effects, so monitoring is necessary. Regular examinations or treatments should be sought if there are symptoms of nasal infection or abnormal changes in the nasal mucosa. Patients at high risk for exposure to chickenpox or measles should focus on infection prevention and early diagnosis, and effects may not appear within the first 48 hours after initial administration. When administered to children, regular monitoring for growth delays is necessary, and it is recommended to use the minimum effective dose. Elderly patients should be monitored closely for changes in physiological functions. There is no specific treatment required for overdose, but systemic corticosteroid side effects may occur, so caution is advised. Before use, shake the container well and perform a test spray; do not spray directly into the eyes or nasal septum but use it only in the nasal cavity. Keep out of reach of children, and the effects on driving or operating machinery are not known.

Serious side effects

Hives, severe swelling, chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions, severe rash with fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes, severe skin reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever, respiratory issues, yellowing of skin or eyes (jaundice), extreme lethargy, liver abnormalities (jaundice), sudden and severe reactions.

Mild side effects

Headache, viral infections, pharyngitis, nosebleeds/blood-stained mucus, cough, upper respiratory infections, menstrual discomfort, musculoskeletal pain, sinusitis, vomiting, joint pain, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, indigestion, ear pain, cold symptoms, muscle pain, nausea, rhinitis, diarrhea, nasal inflammation, otitis media, wheezing, skin trauma, nasal symptoms (irritation, itching, dryness, pain, redness, discomfort, etc.), positive fungal test in the nose.

Store this medication in a tightly sealed container to protect it from air and moisture, preferably in a cool place between 2 and 25 degrees Celsius.

Appearance

An opaque suspension that is white or almost white, contained in a metered spray bottle.

Package unit

18 mL/bottle